Tumor immunity

1. Tumor Immunity Cancer is a major health problem worldwide and one of the most important causes of morbidity and mortality in children and adults. The lethality of malignant tumors is due to their uncontrolled growth within normal tissues, causing damage and functional impairment. The malignant phenotype of cancers reflects defects in regulation of cell proliferation, resistance of the tumor cells to apoptotic death, ability of the tumor cells to invade host tissues and metastasize to distant sites, and tumor evasion of host immune defense mechanisms. The existence of immune surveillance has been demonstrated by the increased incidence of some types of tumors in immunocompromised experimental animals and humans. It is now clear that the innate and adaptive immune systems do react against many tumors, and exploiting these reactions to specifically destroy tumors remains an important goal of tumor immunologists. Several characteristics of tumor antigens and immune responses to tumors are fundamental to an understanding of tumor immunity and for the development of strategies for cancer immunotherapy. The existence of specific anti-tumor immunity implies that tumors must express antigens that are recognized as foreign by the host. The earliest classification of tumor antigens was based on their patterns of expression. Antigens that are expressed on tumor cells but not on normal cells are called tumor-specific antigens; some of these antigens are unique to individual tumors, whereas others are shared among tumors of the same type. Tumor antigens that are also expressed on normal cells are called tumor-associated antigens; in most cases, these antigens are normal cellular constituents whose expression is aberrant or dys-regulated in tumors. The modern classification of tumor antigens is based on the molecular structure and source of antigens expressed by tumor cells that stimulate T cell or antibody responses in their hosts. http://www.creative-diagnostics.com/Tumor-Immunity.htm